A randomised controlled trial of prophylactic versus no-prophylactic platelet transfusions in patients with haematological malignancies

The National Blood Service (UK)0 个研究点目标入组 600 人开始时间: 2006年9月12日最近更新: 2022年2月7日

适应症

试验速览

•1. They are aged 16 years or over
•2. They have a confirmed diagnosis of a haematological malignancy
•3. They are receiving or are going to receive myelosuppressive chemotherapy on this hospital admission with or without haematopoietic stem cell support (this includes patients undergoing haemopoietic stem cell transplantation - autograft or allograft)
•4. They are thrombocytopenic or expected to become thrombocytopenic with a platelet count of less than 50 x 10^9/L for at least five days
•5. They are able to comply with treatment and monitoring

•1. They have had a World Health Organization (WHO) Grade three or four bleed (refer to Modified WHO Bleeding Criteria) during any stage of their treatment to date
•2. During the current admission, they have experienced or are currently experiencing a WHO Grade two or greater bleed
•3. They have any inherited clotting disorder (e.g. haemophilia)
•4. They need to remain on regular aspirin (or related drugs), or will require regular therapeutic doses of anticoagulants (heparin), during the whole period of thrombocytopenia
•5. They have acute promyelocytic leukaemia
•6. They have known HLA antibodies
•7. They are pregnant
•8. They have previously been randomised in this trial at any stage of their treatment

发起方

The National Blood Service (UK)